Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters











Publication year range
1.
Cell Signal ; 65: 109442, 2020 01.
Article in English | MEDLINE | ID: mdl-31639492

ABSTRACT

Most neurodegenerative diseases show a disruption of autophagic function and display abnormal accumulation of toxic protein aggregates that promotes cellular stress and death. Therefore, induction of autophagy has been proposed as a reasonable strategy to help neurons clear abnormal protein aggregates and survive. The kinase mammalian target of rapamycin (mTOR) is a major regulator of the autophagic process and is regulated by starvation, growth factors, and cellular stressors. The phosphoinositide 3-kinase (PI3K)/ protein kinase B (Akt) pathway, which promotes cellular survival, is the main modulator upstream of mTOR, and alterations in this pathway are common in neurodegenerative diseases, e.g. Alzheimer's disease (AD) and Parkinson's disease (PD). In the present work we revised mammalian target of rapamycin complex 1 (mTORC1) pathway and mTORC2 as a complementary an important element in mTORC1 signaling. In addition, we revised the extracellular signal regulated kinase (ERK) pathway, which has become relevant in the regulation of the autophagic process and cellular survival through mTORC2 signaling. Finally, we summarize novel compounds that promote autophagy and neuronal protection in the last five years.


Subject(s)
Autophagy/drug effects , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/pathology , TOR Serine-Threonine Kinases/metabolism , Animals , Humans , Models, Biological , Signal Transduction/drug effects
2.
Oxid Med Cell Longev ; 2016: 7981397, 2016.
Article in English | MEDLINE | ID: mdl-28053694

ABSTRACT

Cervical cancer is the second leading cause of death among Mexican women. The treatment with cis-diamminedichloroplatinum (II) (CDDP) has some serious side effects. Alpha-mangostin (α-M), has a protective effect against CDDP-induced nephrotoxicity, as well as antioxidant, antitumor, and anti-inflammatory properties. Hence, we explored the in vitro and in vivo effect of α-M on human cervical cancer cell proliferation when combined with CDDP. In vitro, The cytotoxic effect of α-M and/or CDDP was measured by the 3-(3,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium assay. Meanwhile, apoptosis, reactive oxygen species (ROS) production, and the cell cycle were determined with flow cytometry. For α-M+CDDP treatment, both a coincubation and preincubation scheme were employed. In vivo, xenotransplantation was performed in female athymic BALB/c (nu/nu) mice, and then tumor volume and body weight were measured weekly, whereas α-M interfered with the antiproliferative activity of CDDP in the coincubation scheme, with preincubation with α-M+CDDP showing significantly greater cytotoxicity than CDDP or α-M alone, significantly inhibiting average tumor volume and preventing nephrotoxicity. This effect was accompanied by increased apoptosis and ROS production by HeLa cervical cancer cells, as well as an arrest in the cell cycle. These results suggest that α-M may be useful as a neoadjuvant agent in cervical cancer therapy.


Subject(s)
Apoptosis/drug effects , Cisplatin/toxicity , Uterine Cervical Neoplasms/pathology , Xanthones/pharmacology , Animals , Biomarkers/metabolism , Cell Cycle/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Drug Interactions , Drug Synergism , Female , HeLa Cells , Humans , Mice, Inbred BALB C , Mice, Nude , Reactive Oxygen Species/metabolism , Time Factors , Tumor Burden/drug effects
3.
Cell Signal ; 26(12): 2694-701, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25173700

ABSTRACT

Disruption of autophagy plays an import role in neurodegenerative disorders, where deficient elimination of abnormal and toxic protein aggregates promotes cellular stress, failure and death. Therefore, induction of autophagy has been proposed as a reasonable strategy to help neurons clear abnormal protein aggregates and survive. The kinase mammalian target of rapamycin (mTOR) is a major regulator of the autophagic process and is regulated by starvation, growth factors, and cellular stressors. Upstream of mTOR the survival PI3K/AKT pathway modulates mTOR activity that is also altered in neurodegenerative diseases of Alzheimer and Parkinson. Nevertheless, the interplay between the PI3K/AKT/mTOR pathway and the autophagic process is complex and a more detailed examination of tissue from patients suffering neurodegenerative diseases and of animal and cellular models is needed. In the present work we review the recent findings on the role of the PI3K/AKT/mTOR pathway in the modulation of the autophagic process in neuronal protection.


Subject(s)
Neurodegenerative Diseases/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein Aggregates/physiology , Proto-Oncogene Proteins c-akt/metabolism , TOR Serine-Threonine Kinases/metabolism , Animals , Autophagy/physiology , Humans , Neurons/metabolism , Signal Transduction/physiology
4.
Food Chem Toxicol ; 49(10): 2631-7, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21802473

ABSTRACT

Cis-diamminedichloroplatinum II (CDDP)-induced nephrotoxicity is associated with the overproduction of reactive oxygen species. tert-Butylhydroquinone (tBHQ) is a compound widely used as food antioxidant. The purpose of this study was to investigate the ability of tBHQ to prevent the nephrotoxic effect of CDDP in rats as well as the mechanisms involved. Thirty-six Wistar rats divided in the following groups were used: control, tBHQ (12.5mg/kg), CDDP (7.5mg/kg) and tBHQ+CDDP. Twenty-four h urine was collected at the beginning and at the end of the experiment and the rats were sacrificed 72h after CDDP-administration. Histological studies were performed and markers of renal function and oxidative/nitrosative stress were measured. In addition, the activity of the following antioxidant enzymes was measured: glutathione peroxidase (GPx), superoxide dismutase (SOD), glutathione reductase (GR) and glutathione-S-transferase (GST). CDDP-induced renal dysfunction, structural damage and oxidative/nitrosative were prevented by tBHQ. In addition, tBHQ completely prevented the CDDP-induced fall in GPx and GST activities. In conclusion, the present study indicates that the antioxidant activity of tBHQ is associated with its nephroprotective effect against CDDP-induced acute kidney injury in rats.


Subject(s)
Antioxidants/pharmacology , Cisplatin/toxicity , Hydroquinones/pharmacology , Kidney Diseases/chemically induced , Kidney Diseases/prevention & control , Aldehydes/metabolism , Animals , Catalase/blood , Glutathione Peroxidase/blood , Glutathione Reductase/blood , Glutathione Transferase/blood , Immunohistochemistry , Kidney Diseases/metabolism , Male , Malondialdehyde/metabolism , Oxidative Stress/drug effects , Random Allocation , Rats , Rats, Wistar , Superoxide Dismutase/blood
5.
Free Radic Res ; 43(11): 1122-32, 2009.
Article in English | MEDLINE | ID: mdl-19863372

ABSTRACT

Cisplatin (CDDP) is a chemotherapeutic agent that produces nephrotoxicity associated with oxidative/nitrosative stress. alpha-Mangostin (alpha-M) is a xanthone extracted from mangosteen with antioxidant and anti-inflammatory properties. The purpose of this study was to evaluate the renoprotective effect of alpha-M on the CDDP-induced nephrotoxicity. alpha-M was administered (12.5 mg/kg/day, i.g.) for 10 days (7 days before and 3 days after CDDP injection). On day 7, rats were treated with a single injection of CDDP (7.5 mg/Kg, i.p.); 3 days after the rats were killed. alpha-M attenuated renal dysfunction, structural damage, oxidative/nitrosative stress, decrease in catalase expression and increase in mRNA levels of tumour necrosis factor alpha and transforming growth factor beta. In conclusion the renoprotective effect of alpha-M on CDDP-induced nephrotoxicity was associated with the attenuation in oxidative/nitrosative stress and inflammatory and fibrotic markers and preservation of catalase activity.


Subject(s)
Cisplatin/toxicity , Kidney Diseases/chemically induced , Kidney Diseases/prevention & control , Xanthones/pharmacology , Animals , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/toxicity , Antioxidants/pharmacology , Cisplatin/pharmacokinetics , Drug Interactions , Kidney Diseases/metabolism , Male , Oligonucleotide Array Sequence Analysis , Oxidative Stress/drug effects , Rats , Rats, Wistar
6.
Food Chem Toxicol ; 46(10): 3227-39, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18725264

ABSTRACT

Many tropical plants have interesting biological activities with potential therapeutic applications. Garcinia mangostana Linn. (GML) belongs to the family of Guttiferae and is named "the queen of fruits". It is cultivated in the tropical rainforest of some Southeast Asian nations like Indonesia, Malaysia, Sri Lanka, Philippines, and Thailand. People in these countries have used the pericarp (peel, rind, hull or ripe) of GML as a traditional medicine for the treatment of abdominal pain, diarrhea, dysentery, infected wound, suppuration, and chronic ulcer. Experimental studies have demonstrated that extracts of GML have antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, and antiviral activities. The pericarp of GML is a source of xanthones and other bioactive substances. Prenylated xanthones isolated from GML have been extensively studied; some members of these compounds possess antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, antifungal and antiviral properties. Xanthones have been isolated from pericarp, whole fruit, heartwood, and leaves. The most studied xanthones are alpha-, beta-, and gamma-mangostins, garcinone E, 8-deoxygartanin, and gartanin. The aim of this review is to summarize findings of beneficial properties of GML's extracts and xanthones isolated from this plant so far.


Subject(s)
Garcinia mangostana/chemistry , Plant Extracts/chemistry , Plant Extracts/pharmacology , Fruit/chemistry , Plant Leaves/chemistry , Plant Stems/chemistry , Xanthones/chemistry , Xanthones/pharmacology
7.
Am J Physiol Renal Physiol ; 289(5): F1020-30, 2005 Nov.
Article in English | MEDLINE | ID: mdl-15998842

ABSTRACT

We showed that spironolactone reduced structural damage and prevented renal dysfunction in chronic cyclosporine (CsA) nephrotoxicity. These findings evidenced an aldosterone renal vascular effect under this condition. To investigate aldosterone's role in modulating renal vascular tone, renocortical vasoactive pathways mRNA levels in chronic CsA nephrotoxicity as well as spironolactone's effect on renal function in acute CsA nephrotoxicity were evaluated. Two experimental sets were designed. For chronic nephrotoxicity, rats fed with low-sodium diet were divided into groups receiving vehicle, spironolactone (Sp), CsA, and CsA+Sp, for 21 days. Creatinine clearance, survival percentage, and renocortical mRNA levels of pro-renin, angiotensinogen (Ang), angiotensin receptors (AT(1A), AT(1B), and AT(2)), preproendothelin, endothelin receptors (ET(A), ET(B)), cyclooxygenase-2 (COX-2), and adenosine receptors (Ad(1), Ad(2A), Ad(2B), and Ad(3)) were analyzed. For acute nephrotoxicity, similar groups fed with a standard chow diet for 7 days were included. Serum potassium and sodium, glomerular filtration rate (GFR), and renal blood flow (RBF) were determined. In chronic model, CsA produced pro-renin and ET upregulation, altered adenosine receptors expression, and reduced Ang, AT(1A), AT(1B), ET(B), and COX-2 mRNA levels. Spironolactone protective effect in chronic nephrotoxicity was associated with prevention of pro-renin upregulation and increased AT(2), together with ET(B) reduction. In acute nephrotoxicity, spironolactone completely prevented GFR and RBF reduction induced by CsA. Our results suggest that aldosterone contributes to renal vasoconstriction observed in CsA nephrotoxicity and that renoprotection conferred by spironolactone was related to modification of renocortical vasoactive pathways expression, in which pro-renin normalization was the most evident change in chronic nephropathy. Finally, our data point to spironolactone as a potential treatment to reduce CsA nephrotoxicity in transplant patients.


Subject(s)
Aldosterone/physiology , Kidney Cortex/physiology , Mineralocorticoid Receptor Antagonists/pharmacology , Spironolactone/pharmacology , Animals , Cyclosporine/toxicity , Immunosuppressive Agents/toxicity , Male , Organ Transplantation , RNA, Messenger/biosynthesis , Rats , Rats, Wistar , Receptors, Endothelin/biosynthesis , Renin-Angiotensin System/physiology
8.
Rev. invest. clín ; Rev. invest. clín;57(2): 147-155, mar.-abr. 2005. ilus, tab
Article in Spanish | LILACS | ID: lil-632499

ABSTRACT

Calcineurin inhibitors are helpful ímmunosuppressíve agents in clinical practice. Thanks to their lower cost respect with new ímmunosuppressíve therapy, calcineurin inhibitors in our country continue being the most used treatment in solid organ transplant recipients or patients with autoimmune disease. In the 80's decade cyclosporine A (CsA) was introduced as the first calcineurin inhibitor transforming the immunosuppression therapy. Up to date, many articles evaluating beneficial and adverse effects of CsA have been published. In this review, basic aspects and actions of CsA are analyzed together with studies from our laboratory that pointed out the pathophysiological role of aldosterone as a mediator of functional and structural changes that are observed in CsA nephrotoxicity. Based in our findings, we proposed that in CsA nephrotoxicity, the aldosterone mediates renal vasoconstriction and enhances TGFJ3 expression promoting the development of nefrotoxicity. Finally, results from our laboratory and others allow us to suggest that aldosterone receptors blockade with spironolactone or eplerone could be a pharmacological therapy to reduce or prevent acute and chronic CsA nephrotoxicity in transplant recipients.


Los inhibidores de calcineurina son los agentes inmunosupresores más potentes con los que se cuenta en la práctica clínica, y gracias a su bajo costo respecto a las nuevas terapias inmunosupresoras, en nuestro país continúan siendo los agentes terapéuticos más utilizados para el manejo de pacientes con enfermedades autoinmunes o que reciben trasplantes. En la década de los 80's se introdujo la ciclosporina A (CsA) como primer inhibidor de calcineurina, lo cual revolucionó la terapia inmunosupresora. Desde entonces se han publicado muy variados artículos donde se han evaluado los efectos benéficos y deletéreos de estos inhibidores; específicamente nos enfocaremos a revisar las acciones de CsA y, en particular, los resultados de nuestro laboratorio que muestran el papel fisiopatológico que juega la aldosterona como mediador de los cambios funcionales y estructurales que se observan en la nefrotoxicidad por ciclosporina. Específicamente su participación en promover la vasoconstricción renal asociada a CsA y en el desarrollo de fibrosis al inducir la expresión de TGFβ. Por lo tanto, nuestros resultados y los de otros autores nos permiten proponer el bloqueo de los receptores de aldosterona con espironolactona o eplerone como un tratamiento farmacológico útil para reducir la incidencia de nefrotoxicidad aguda y crónica, inducida por CsA en pacientes con enfermedades autoinmunes o que reciben trasplante de órganos.


Subject(s)
Animals , Humans , Aldosterone/physiology , Calcineurin/antagonists & inhibitors , Cyclosporine/adverse effects , Graft Rejection/prevention & control , Immunosuppressive Agents/adverse effects , Kidney Diseases/chemically induced , Cardiovascular Diseases/physiopathology , Disease Progression , Free Radicals , Graft Rejection/immunology , Kidney Diseases/physiopathology , Kidney Diseases/prevention & control , NFATC Transcription Factors/physiology , Receptors, Mineralocorticoid , Renal Circulation/physiology , Renin-Angiotensin System/physiology , Spironolactone/analogs & derivatives , Spironolactone/therapeutic use , Sympathetic Nervous System/physiopathology , T-Lymphocytes, Cytotoxic/immunology , Transplantation Immunology , Transforming Growth Factor beta/physiology , Vasoconstriction/physiology
9.
Rev Invest Clin ; 57(2): 147-55, 2005.
Article in Spanish | MEDLINE | ID: mdl-16524053

ABSTRACT

Calcineurin inhibitors are helpful immunosuppressive agents in clinical practice. Thanks to their lower cost respect with new immunosuppressive therapy, calcineurin inhibitors in our country continue being the most used treatment in solid organ transplant recipients or patients with autoimmune disease. In the 80's decade cyclosporine A (CsA) was introduced as the first calcineurin inhibitor transforming the immunosuppression therapy. Up to date, many articles evaluating beneficial and adverse effects of CsA have been published. In this review, basic aspects and actions of CsA are analyzed together with studies from our laboratory that pointed out the pathophysiological role of aldosterone as a mediator of functional and structural changes that are observed in CsA nephrotoxicity. Based in our findings, we proposed that in CsA nephrotoxicity, the aldosterone mediates renal vasoconstriction and enhances TGFbeta expression promoting the development of nefrotoxicity. Finally, results from our laboratory and others allow us to suggest that aldosterone receptors blockade with spironolactone or eplerone could be a pharmacological therapy to reduce or prevent acute and chronic CsA nephrotoxicity in transplant recipients.


Subject(s)
Aldosterone/physiology , Calcineurin Inhibitors , Cyclosporine/adverse effects , Graft Rejection/prevention & control , Immunosuppressive Agents/adverse effects , Kidney Diseases/chemically induced , Animals , Cardiovascular Diseases/physiopathology , Disease Progression , Eplerenone , Free Radicals , Graft Rejection/immunology , Humans , Kidney Diseases/physiopathology , Kidney Diseases/prevention & control , Mineralocorticoid Receptor Antagonists , NFATC Transcription Factors/physiology , Receptors, Mineralocorticoid/physiology , Renal Circulation/physiology , Renin-Angiotensin System/physiology , Spironolactone/analogs & derivatives , Spironolactone/therapeutic use , Sympathetic Nervous System/physiopathology , T-Lymphocytes, Cytotoxic/immunology , Transforming Growth Factor beta/physiology , Transplantation Immunology , Vasoconstriction/physiology
10.
Article in English | MEDLINE | ID: mdl-14659452

ABSTRACT

The recent finding that mitochondria contain a nitric oxide (NO) synthase suggests that this compound is involved in the regulation of various mitochondrial functions. Monoamine oxidase (MAO) is embedded in the outer mitochondrial membrane. NO modulates membrane fluidity. Thus, the aim of the present work was to study the effect of NO on mitochondrial MAO activity and membrane fluidity. An outer mitochondrial membrane fraction (OMMF) was obtained from rat liver. OMMF was incubated with various concentrations of S-nitroso-N-acetylpenicillamine (SNAP), a NO donor. MAO activity and fluidity were measured by a spectrophotometric assay and by the polarization of fluorescence technique, respectively. It was found that small concentrations of SNAP (0.4-40 microM) were capable of inhibiting MAO activity but unable to decrease fluidity significantly. In contrast, larger amounts of SNAP (40-300 microM) effectively decreased membrane fluidity, but were not able to further decrease MAO activity. This information suggests that mitochondrial MAO and membrane fluidity possess different sensitivity to the effect of NO. Unfortunately, the mechanism by which NO inhibits MAO remains unknown at present. However, it seems likely that the effect of NO on MAO activity is by a direct interaction of the compound or a metabolite to the protein.


Subject(s)
Intracellular Membranes/physiology , Membrane Fluidity/physiology , Mitochondria, Liver/enzymology , Monoamine Oxidase Inhibitors/metabolism , Monoamine Oxidase/metabolism , Nitric Oxide/metabolism , Penicillamine/analogs & derivatives , Animals , Dose-Response Relationship, Drug , Intracellular Membranes/drug effects , Male , Membrane Fluidity/drug effects , Mitochondria, Liver/drug effects , Nitric Oxide Donors/pharmacology , Penicillamine/pharmacology , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL